Research institute

Vilcek Foundation Awards $500,000 in Prizes to Immigrant Scientists and Designers

Retrieved on: 
Tuesday, February 6, 2024
Vilcek Foundation, Research institute, Bacteria, MD, Biochemistry, National academy, Chronic liver disease, Anatomy, Organization, Humanities, Bangladesh Technical Education Board, History, American Academy, Hepatology, Biomedical sciences, IRS, CRISPR, Medicine, University, Student, Foundation (nonprofit), Pratt Institute, Human, Howard Hughes Medical Institute, Work, Organoid, Brain, Doctor of Philosophy, Rockefeller University, Cancer, Art, Research, Cell, Stem cell, Wheelchair, Pharmaceutical industry

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- The Vilcek Foundation announces the recipients of the 2024 Vilcek Foundation Prizes. Comprising a total of $500,000 in awards, the prizes align with the foundation's mission and vision: To celebrate immigrant professionals in biomedical science and in the arts and humanities, and to recognize immigrant professionals' contributions to intellectual and cultural life in the United States.

Key Points: 
  • NEW YORK, Feb. 6, 2024 /PRNewswire/ -- The Vilcek Foundation announces the recipients of the 2024 Vilcek Foundation Prizes .
  • Vilcek Foundation awards $500,000 in prizes to immigrant professionals in Biomedical Science and Design.
  • In 2024, four prizes are awarded each in Biomedical Science and in Design: one $100,000 Vilcek Prize, and three $50,000 Vilcek Prizes for Creative Promise.
  • "The United States' leadership in biomedical science and research is in no small part due to the contributions of immigrant scientists," says Jan Vilcek, Chairman and CEO of the Vilcek Foundation.

Fragrance ingredient exposure is orders of magnitude below thresholds of concern, study shows

Retrieved on: 
Tuesday, February 6, 2024
Toxicity, Research institute, EFSA, DST, Trauma surgery, Food, Inhalation, Non-Euclidean geometry, Doctor of Philosophy, TTC, Perfume

MAHWAH, N.J., Feb. 6, 2024 /PRNewswire/ -- The Research Institute for Fragrance Materials, Inc. (RIFM), in collaboration with scientific modeling, data analytics, and computing company Creme Global, compared the fragrance exposure of the highest-end product users to the Threshold of Toxicological Concern (TTC) and Dermal Sensitization Threshold (DST) to determine a realistic understanding of consumer exposure to fragrance. The TTC is based on the U.S. Food and Drug Administration's Threshold of Regulation, which it expands upon to include consideration of an ingredient's molecular structure in conjunction with its toxicity data. The TTC approach is internationally recognized by regulators including the European Food Safety Authority (EFSA).

Key Points: 
  • The TTC approach is internationally recognized by regulators including the European Food Safety Authority (EFSA) .
  • The study authors compared exposure to the approximately 3,000 in-use fragrance-producing ingredients to their respective TTCs and DSTs.
  • Representative fragrance ingredients were randomly selected and analyzed for exposure distribution by product type (i.e., personal, household, oral, and air care) and route of exposure.
  • Exposure calculations were performed by the Creme-RIFM Aggregate Exposure model, which provides realistic exposure estimates that consider all fragrances the population is exposed to across all products used.

New Leap in Flexible Electronics: MANA's Breakthrough Doping Innovation

Retrieved on: 
Tuesday, February 6, 2024
Polymer, Electronics, Proton, Water, Electron, Semiconductor, HQ, Research institute, MANA, Laser

Doping involves the addition of dopants to the semiconductor via a redox reaction to increase the density of charge carriers.

Key Points: 
  • Doping involves the addition of dopants to the semiconductor via a redox reaction to increase the density of charge carriers.
  • "The Fermi level of the semiconductors was precisely and reproducibly tuned by the pH of the doping solution," says Dr. Yamashita.
  • Moreover, such precise doping was conducted in ambient air for the first time, demonstrating unprecedented scalability suitable for device manufacturing.
  • This innovative doping method offers a cost-effective approach for developing flexible and stable electronics, such as wireless sensors, energy-harvesting modules, biomolecular devices, displays, and solar cells.

PDA Announces Collaboration with the U.S. FDA Concerning Services for Pharma Compounders

Retrieved on: 
Monday, February 5, 2024
Online, Partnership, Policy, Interest group, Human services, Research institute, Curriculum, Eli Lilly, Patient, FDA, Publication, PPD, PDA, Food, Name, Virtual, Pharmacy, Conference, CGMP, Hospital, Pharmaceutical industry

BETHESDA, Md., Feb. 5, 2024 /PRNewswire-PRWeb/ -- PDA is proud to announce a new four-year collaboration with the U.S. Food and Drug Administration's (FDA) Compounding Quality Center of Excellence, established to support outsourcing facilities and related stakeholders in their efforts to provide high-quality drugs for patients who need them. Through the partnership, PDA will expand its current training course opportunities for professionals in the outsourcing facility and compounding community and establish an ongoing interactive in-person and virtual interest group forum.

Key Points: 
  • Michael Porter has joined the PDA Education team to oversee the deployment of the new training courses and to liaise with the FDA.
  • He brings a wealth of experience and expertise to PDA, having worked previously for Pharmatech Associates, a USP Company, PPD, and Eli Lilly.
  • The training courses will take advantage of the entire gambit of multimedia modalities, including in-person, virtual, and self-guided online training courses.
  • This new interest group will launch at PDA Week 2024 followed by virtual meetings starting in April and May.

UNDERGRADUATE ENROLLMENT GREW IN THE FALL OF 2023

Retrieved on: 
Wednesday, January 24, 2024
Student, Community, Research, Education sciences, ARCC, Salt cellar, National Student Clearinghouse, Columbia University, Research institute, Community college, Nursing credentials and certifications, Teachers College, Columbia University, Education, Growth, Nursing

Herndon, VA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Undergraduate enrollment grew 1.2 percent (+176,000) in the fall of 2023, the first increase since the pandemic, according to the National Student Clearinghouse’s latest research.

Key Points: 
  • Herndon, VA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Undergraduate enrollment grew 1.2 percent (+176,000) in the fall of 2023, the first increase since the pandemic, according to the National Student Clearinghouse’s latest research.
  • “The small uptick this fall is a welcome change for higher education, but there are still over a million empty seats on campuses today that were filled five years ago.”
    The Current Term Enrollment Estimates (CTEE) report showed that freshman enrollment also grew this fall, but at a slower rate (+0.8%, +18,000) than undergraduate enrollment overall.
  • Despite these gains, associate enrollment remains 14.2 percent below fall 2019 levels, and bachelor’s enrollment remains 3.3 percent below 2019.
  • At community colleges with a high vocational program focus, enrollment grew 16.0 percent (+112,000), bringing them above fall 2019 levels (+3.7%).

Commons Clinic Launches the Center for Spine Economics, Outcomes & Research to Pioneer Spinal Restoration Care Model

Retrieved on: 
Wednesday, January 10, 2024
Entrepreneurship, LOS, Spinal fusion, Patient, Research, Injection, Medicare, Economics, MSK, Spine, Ecosystem, Chairperson, Quality of life, Low back pain, Publishing, Pain, Research institute, Robotics, Physician

LOS ANGELES, Jan. 10, 2024 /PRNewswire/ -- Commons Clinic, a leading value-based physician group reinventing musculoskeletal (MSK) care, today announced the launch of the Center for Spine Economics, Outcomes & Research, accelerating the deployment of innovative care models for the treatment and management of spine conditions. The Center will introduce a center-of-excellence program for spinal restoration focusing on motion preservation, minimally invasive and ultra-minimally invasive procedures, and biologic treatments, while committing to investing $100M over the next decade to transform ambulatory spinal care delivery. Founding physicians Dr. Hyun Bae and Dr. Sanjay Khurana will lead the Center's programming and evangelize its high-value spine model with the next generation of spine specialists and ecosystem partners. 

Key Points: 
  • "The Center for Spine Economics, Outcomes & Research will illuminate the path forward from obsolete hospital-based spine care models, equipping physicians with the latest spine care research, state-of-the art facilities and technology, and evidence-based, high-value care delivery models."
  • The Center will share resources with the Commons Clinic physician group, which rearchitects the core of an integrated delivery network.
  • "With the Center for Spine Economics, Outcomes & Research, Commons Clinic is committing to a multi-decade investment with the sole mission of reversing the societal burden of low back pain and spine maladies.
  • Those interested in participating in Commons Clinic's Center for Spine Economics, Outcomes & Research can visit: commonsclinic.com.

ChromaCode Announces Appointment of Mark McDonough as Chairman

Retrieved on: 
Wednesday, January 10, 2024
Memorial, Chairperson, Pharming, NGS, Medicine, Biotechnology, Princeton University, Molecular biology, Credit Suisse, Cancer prevention, Genomics, Laboratory, Research institute, Biomarker, Retirement, Doctor of Philosophy, NEA, Nested polymerase chain reaction, Management

CARLSBAD, Calif., Jan. 10, 2024 /PRNewswire/ -- ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, announces Mark McDonough as Chair of the Board, the retirement of former Chair Carol Gallagher, Pharm.D., and the appointment of Michele Park, Ph.D. to the Board.

Key Points: 
  • CARLSBAD, Calif., Jan. 10, 2024 /PRNewswire/ -- ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, announces Mark McDonough as Chair of the Board, the retirement of former Chair Carol Gallagher, Pharm.D., and the appointment of Michele Park, Ph.D. to the Board.
  • Mark McDonough, CEO of ChromaCode, becomes Chair of the Board, effective January 1, 2024.
  • Retiring Chair, Carol Gallagher commented, "A year ago, we were fortunate to have Mark join ChromaCode as CEO.
  • Now, we are thrilled to announce the appointment of Mark as Chair of our Board of Directors.

American Lung Association Celebrates 120 Years of Impact: A Legacy of Advancing Lung Health and Saving Lives

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Quality of life, Herbal cigarette, Immune system, RSV, Doonesbury, Pneumonia, Research, American Lung Association, Smoking, National Association, Lung cancer, Education, Asthma, Study, COVID-19, Climate change, Public, Investment, Research institute, Pharmaceutical industry

The Lung Association pioneered a groundbreaking model of education, advocacy and research to address critical public health and lung health issues.

Key Points: 
  • The Lung Association pioneered a groundbreaking model of education, advocacy and research to address critical public health and lung health issues.
  • Congratulations to the American Lung Association on 120 years of fighting for air," said Garry Trudeau, great grandson of the founder of the Lung Association and creator of the Doonesbury comic strip.
  • "The American Lung Association has an incredible history of being at the forefront of lung health and improving public health across the United States.
  • Join the American Lung Association in their journey to champion lung health and help celebrate 120 years of impact.

Plus Updates Financial and Cash Guidance for 2024

Retrieved on: 
Monday, December 18, 2023
Therapy, Burn, Central nervous system, Cancer, Patient, Rhenium, Plus Therapeutics, PSTV, Research institute, CNS, LM, Pharmaceutical industry

AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance for 2024.

Key Points: 
  • AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance for 2024.
  • Plus is currently in the second year of a Cancer Prevention and Research Institute of Texas (CPRIT) award totaling $17.8 million.
  • The Company forecasts an additional $6.9 million in grant revenue during the 2024 calendar year.
  • “This combination of forecasted non-dilutive grant revenue and debt restructuring significantly strengthens our balance sheet and reduces our burn,” said Andrew Sims, Chief Financial Officer of Plus Therapeutics.

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Retrieved on: 
Wednesday, December 13, 2023
Melanoma, CAB, PR, Survival, Tumor microenvironment, DLT, PD-1, Incidence, Nivolumab, MD, SAN, Therapy, Cancer, Toxicity, Conditional, Ipilimumab, Patient, Translational research, Research institute, Pharmaceutical industry

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent.

Key Points: 
  • BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent.
  • The event will feature Omid Hamid, MD, Chief, Translational Research and Immunotherapy, and Director, Melanoma Therapeutics at The Angeles Clinic and Research Institute, and highlights Phase 1 dose escalation trial results for BA3071.
  • In addition, the relatively low incidence of immune-related adverse events suggests our CAB antibody has the potential to address the current limitations of CTLA-4-targeted therapies."
  • Exposure levels of BA3071 were similar to that of ipilimumab analog, with significantly less GI toxicity when combined with nivolumab in a non-human primate model.